Scinai Immunotherapeutics 达成 1500 万美元股权购买协议

The latest update is out from Scinai Immunotherapeutics ( (SCNI) ).

On September 10, 2025, Scinai Immunotherapeutics Ltd. entered into a Standby Equity Purchase Agreement with YA II PN, LTD., allowing the company to sell up to $15 million of its American Depositary Shares over the next 36 months. This agreement provides Scinai with financial flexibility to raise capital as needed, potentially impacting its market position by enhancing its operational capabilities and investor confidence. The agreement includes conditions such as a registration statement with the SEC and limits on Yorkville’s ownership to prevent exceeding 9.99% of the company’s voting power.

Spark’s Take on SCNI Stock

According to Spark, TipRanks’ AI Analyst, SCNI is a Neutral.

Scinai Immunotherapeutics is undergoing a financial recovery but faces significant challenges such as negative cash flows and high debt levels. The stock shows neutral technical indicators, suggesting moderate market confidence. Its attractive valuation might appeal to value investors, but the absence of dividends and financial risks may deter more conservative investors.

To see Spark’s full report on SCNI stock, click here.

More about Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd. operates in the biotechnology industry, focusing on the development and commercialization of therapeutic products. The company is based in Jerusalem, Israel, and its primary market focus includes the sale of American Depositary Shares (ADSs) on the Nasdaq Stock Market under the symbol ‘SCNI’.

Average Trading Volume: 1,111,139

Technical Sentiment Signal: Sell

Current Market Cap: $1.31M

For a thorough assessment of SCNI stock, go to TipRanks’ Stock Analysis page.